This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

/C O R R E C T I O N -- Robbins Arroyo LLP/

In the news release, Attention CytRx Corporation Investors: CytRx Misled Investors According to a Recently Filed Class Action, issued 21-Mar-2014 by Robbins Arroyo LLP over PR Newswire, we are advised by the company that the third paragraph should read that Steven A. Kriegsman sold $2.1 million of Galena Biopharma, Inc. shares, not CytRx shares as originally issued. The complete, corrected release follows:

Attention CytRx Corporation Investors: CytRx Misled Investors According to a Recently Filed Class Action

SAN DIEGO and LOS ANGELES, March 21, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of CytRx Corporation (NASDAQ: CYTR) has filed a federal securities fraud class action complaint in the U.S. District Court for the Central District of California. The complaint alleges that the company and certain of its officers and directors violated the Securities and Exchange Act of 1934 between November 22, 2013 and March 13, 2014, including the company's public offering on February 5, 2014 (the "Class Period"). CytRx is a biopharmaceutical research and development company specializing in oncology.

Robbins Arroyo LLP

CytRx Is Accused of Engaging in a Misleading Promotional Campaign

According to the complaint, shares of CytRx fell $0.56 per share, or 8.5%, to close at $6.04 on February 12, 2014, following the publication of an article on TheStreet.com claiming that CytRx retained an investor relations firm accused of using deceptive practices to tout its clients' stock. Specifically, the complaint charges that an investor relations firm, the DreamTeamGroup, was hired by CytRx to tout the company and promote its stock. The complaint charges that the DreamTeamGroup misled investors by publishing favorable articles about its clients while falsely stating that the articles were written by authors who were not paid by the company. Then, on March 13, 2014, CytRx's stock fell an additional $0.61 per share to close at $4.17, following the publication of an article on seekingalpha.com detailing the role of CytRx management in editing, and approving the paid for articles.

The complaint further alleges that CytRx's stock traded at artificially high prices because of this misleading campaign, and that CytRx's CEO, President and Director, Steven A. Kriegsman, sold $2.1 million of Galena Biopharma, Inc. shares while that stock was artificially inflated because of a similar promotion employing the DreamTeamGroup. Mr. Kriegsman has been a member of the Board of Directors at Galena since 2006.

CytRx Shareholders Are Encouraged to Contact Shareholder Rights Law Firm Robbins Arroyo

If you invested in CytRx and would like to discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the information form on the firm's shareholder rights blog: www.robbinsarroyo.com/shareholders-rights-blog/cytrx-corporation

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs